Alex Gyftopoulos, MD FACC's Avatar

Alex Gyftopoulos, MD FACC

@agyftomd.bsky.social

Cardiologist @UMMC and Baltimore VA, interested in preventive cardiology, lipidology, and medical education

137 Followers  |  130 Following  |  14 Posts  |  Joined: 21.11.2024
Posts Following

Posts by Alex Gyftopoulos, MD FACC (@agyftomd.bsky.social)

Post image Post image

Reboot! πŸ’” #469 Inpatient Heart Failure Diuresing β€˜til the heart’s content

🩺πŸ₯ΌMaster inpatient heart failure management! Learn key tips for initiating guideline-directed medical therapy, diuretic therapy pearls, and moe! We are joined by Dr. Gurusher Panjrath

🎧 thecurbsiders.com/curbsiders-p...

10.02.2026 15:01 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
A visual representation of the CORALreef Lipids trial, which assessed the efficacy and safety of the oral PCKS9 inhibitor enlicitide decanoate for patients with elevated low-density lipoprotein cholesterol.

A visual representation of the CORALreef Lipids trial, which assessed the efficacy and safety of the oral PCKS9 inhibitor enlicitide decanoate for patients with elevated low-density lipoprotein cholesterol.

Phase 3 CORALreef Lipids trial: PCSK9 inhibitors are an effective alternative to statins for lowering LDL cholesterol, but current formulations are available only in an injectable form. Research findings on an oral PCSK9 inhibitor are summarized in a new Quick Take video. nej.md/4a8fxXz

#MedSky

06.02.2026 20:07 β€” πŸ‘ 6    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0
Original Article | Feb. 5, 2026 
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide (CORALreef Lipids) 

Fig. 1A. Change in LDL Cholesterol Levels. 

NEJM identity sits at the bottom.

Original Article | Feb. 5, 2026 A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide (CORALreef Lipids) Fig. 1A. Change in LDL Cholesterol Levels. NEJM identity sits at the bottom.

In the phase 3 CORALreef Lipids trial, the oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by 57% at 24 weeks and also lowered non-HDL cholesterol, apolipoprotein B, and lipoprotein(a). Adverse events were similar in the two groups. Full trial results: nej.md/4qhQPtQ

#MedSky #CardioSky

04.02.2026 22:10 β€” πŸ‘ 8    πŸ” 5    πŸ’¬ 2    πŸ“Œ 0
Post image

How should ApoB and Lp(a) be used as core measures to assess cardiovascular risk?

Join experts Allan Sniderman, George Thanassoulis and Michael Pencina as they unpack the power of these biomarkers – and what they mean for prevention strategies.

Listen nowπŸ‘‰ bit.ly/3LjJWcC

#ApoB #LipoproteinA

22.10.2025 09:52 β€” πŸ‘ 6    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image

An inclisiran-based treatment strategy for patients with hypercholesterolemia at high risk for #CVD events helped achieve individual LDL-C goals compared with placebo, based on findings from VICTORION-Difference presented at #ESCCongress. Details: https://bit.ly/463MS43

30.08.2025 20:14 β€” πŸ‘ 2    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0
Post image

Treatment with olezarsen significantly reduced triglyceride levels at 6 months compared to placebo in pts w/ moderate hypertriglyceridemia & elevated CV risk, according to results of the Essence-TIMI 73b study presented during #ESCCongress. πŸ”— More: https://bit.ly/4g4r50H

30.08.2025 17:31 β€” πŸ‘ 2    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Preview
Is statin therapy safe for pregnant women? Laxmi Mehta, MD, explained that the use of statins when treating pregnant women is no longer forbidden. However, she added, cardiologists should always discuss it first with their patients.

For Very High Risk Women - Use of Statins in Pregnancy - cardiovascularbusiness.com/topics/clinical/pharmaceutics/statin-therapy-safe-pregnant-women?utm_source=newsletter&utm_medium=cvb_video @nationallipid.bsky.social @escardio.bsky.social @aspcardio.bsky.social @familyheartfdn.bsky.social

13.04.2025 15:33 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
The LDL cumulative exposure hypothesis: evidence and practical applications - Nature Reviews Cardiology In this Review, Catapano and colleagues discuss the evidence supporting the LDL cumulative exposure hypothesis and how measuring cumulative LDL exposure can be used to estimate risk and contribute to ...

Best publication in Preventive Cardiology I have ever read just out in Nature Reviews Cardiology by Ference, Braunwald, and Catapano. Most statin trials only last 4 years, but now it's clear that being on a statin for decades is key to preventing heart attack & stroke. www.nature.com/articles/s41...

09.02.2025 02:11 β€” πŸ‘ 6    πŸ” 4    πŸ’¬ 1    πŸ“Œ 0
Post image Post image

πŸ“’NEW NLA & AGS expert clinical consensus on managing #hypercholesterolemia in adults older than 75 years without a history of #ASCVD.

Read the article now: sciencedirect.com/science/arti...

#Cardiosky

10.04.2025 18:55 β€” πŸ‘ 3    πŸ” 4    πŸ’¬ 0    πŸ“Œ 1
Preview
Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study

ICYMI at #ACC25: #JACCAsia EiC Dr. Jian’an Wang & colleagues presented the results of a phase 2 study demonstrating that SHR-1918, a monoclonal antibody against ANGPTL-3, achieved dose-dependent reductions of LDL

πŸ“„: www.jacc.org/doi/10.1016/... #JACC #ASCVD #CardioSky

10.04.2025 13:41 β€” πŸ‘ 7    πŸ” 5    πŸ’¬ 0    πŸ“Œ 0
Preview
Low-density lipoprotein cholesterol levels and risk of incident dementia: a distributed network analysis using common data models Background The link between low-density lipoprotein cholesterol (LDL-C) levels and dementia risk is poorly understood, with conflicting evidence on the role of LDL-C and the impact of statin therapy o...

More data supporting that lower LDL is better. This time in the context of dementia. jnnp.bmj.com/content/earl...

06.04.2025 13:41 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Some Lp(a) (LPA) genetics - Get tested and if abnormal get adult family members tested and get competent advice. If any clinician, including a cardiologist tells you Lp(a) is not important, is experimental or its risk cannot be treated -- run fast out of that office

15.03.2025 19:53 β€” πŸ‘ 12    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0

A fantastic conference with plenty of informative and insightful presentations!

18.01.2025 02:15 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
ASPC 2024 Enduring Content - American Society for Preventive Cardiology

Missed the 2024 ASPC Congress or want to revisit the highlights? 🩺✨ Discover the enduring content from the event and stay ahead in the field!

πŸ“š Access it all here: www.aspconline.org/aspc-2024-en...

#CardioSky #MedSky #ASPC2024 #MedicalEducation #LifelongLearning

17.01.2025 18:04 β€” πŸ‘ 3    πŸ” 3    πŸ’¬ 0    πŸ“Œ 1
Post image

Redefining obesity. It is time.
πŸ“BMI is NOT a direct measure of fat
πŸ“BMI does NOT establish the distribution of fat
πŸ“BMI cannot determine with excess fat is a health problem
@thelancet.bsky.social
Lancet Commission

πŸ“Ž www.thelancet.com/commissions/...

15.01.2025 05:47 β€” πŸ‘ 31    πŸ” 14    πŸ’¬ 1    πŸ“Œ 1
Infographic panel for the Lancet Diabetes & Endocrinology Commission on diagnosing clinical obesity.

Infographic panel for the Lancet Diabetes & Endocrinology Commission on diagnosing clinical obesity.

πŸ†• Global Commission proposes overhaul of obesity diagnosis – going beyond BMI to define when obesity is a disease.

Find out more: hubs.li/Q030v_j_0

15.01.2025 07:53 β€” πŸ‘ 36    πŸ” 16    πŸ’¬ 2    πŸ“Œ 10
Preview
Women’s Cardiovascular Fellowship program (non-ACGME) Learn about Inova's fellowship program for Women’s Cardiovascular health (non-ACGME)

www.inova.org/our-services...

Please apply with CV, 3LOR and personal statement. We will select our next fellow in January 2025. #CardioOB #Prevention

27.12.2024 00:33 β€” πŸ‘ 11    πŸ” 6    πŸ’¬ 0    πŸ“Œ 1

Ensuring every school is ready for a cardiac emergency is a huge step forward in protecting young hearts. We’re proud to support the #HEARTSact and continue our work with the Smart Heart Sports Coalition.

02.01.2025 22:34 β€” πŸ‘ 9    πŸ” 5    πŸ’¬ 0    πŸ“Œ 0
Preview
Top General Cardiology and Prevention News of 2024 Top General Cardiology and Prevention News of 2024 sciprian@crf.org Mon, 12/23/2024 - 15:21 Caitlin E. Cox The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler strategies.

ICYMI: Top General Cardiology and Prevention News of 2024

02.01.2025 14:03 β€” πŸ‘ 1    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image

Great news in this meta-analysis which showed no increase in cardiovascular events in women undergoing fertility treatments.

academic.oup.com/eurheartj/ad...

29.12.2024 14:45 β€” πŸ‘ 5    πŸ” 5    πŸ’¬ 1    πŸ“Œ 0

More evidence that we should he aggressive when treating risk factors like elevated atherogenic lipoproteins in our patients.

27.12.2024 19:20 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

Congrats to Dr. Sharma & Inova. What a great honor & opportunity for this Ciccarone Center alumnus.

22.12.2024 19:28 β€” πŸ‘ 9    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Preview
Guideline recommended statin eligibility and use among U.S. adults ages 20 to 39 years Guidelines for statin therapy emphasize treatment of adults ages 40–75 years, with less guidance for the treatment of younger adults, ages 20–39 years…

A bit delayed, but finally, here is a Skytorial (Bluetorial?) on our recent study of guideline recommended statin use in younger adults. #CardioSky #MedSky #CVPrev

www.sciencedirect.com/science/arti...

1/

17.12.2024 18:01 β€” πŸ‘ 24    πŸ” 13    πŸ’¬ 1    πŸ“Œ 0

The times - they are a changing! The evolving definition of obesity by the FDA should revolutionize the way think and treat patients

21.12.2024 15:45 β€” πŸ‘ 9    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
How RFK Jr’s Longtime Friend Mark Hyman Built a Wellness Empire Dr. Mark Hyman, a β€œfunctional medicine” proponent and longtime friend of Robert F. Kennedy Jr., is finding powerful allies in his bid to treat disease with blood tests and supplements.

Shocking to see the @nytimes.com give any credibility to Mark Hyman. His strategy is get rich off off supplements that aren’t evidence based & blood tests that also aren’t evidence based.

It’s one thing to be skeptical of research but this is not that.
#CardioSky

www.nytimes.com/2024/12/18/h...

19.12.2024 12:53 β€” πŸ‘ 51    πŸ” 17    πŸ’¬ 6    πŸ“Œ 1
Preview
Polluted Air from Canadian Wildfires and Cardiopulmonary Disease in the Eastern US This case-control study compares rates of clinical encounters for cardiopulmonary disease in the Eastern US following wildfires in Western Canada with previous periods of high air pollution within the...

In this case study of a large medical system, an increased cardiopulmonary disease burden for residents of Maryland that was likely associated with contemporaneous wildfire smoke–based infiltration of polluted or toxic air originating from Western Canada up to 2100 miles remotely was identified

15.12.2024 16:22 β€” πŸ‘ 9    πŸ” 6    πŸ’¬ 1    πŸ“Œ 0
Post image Post image

What’s the relation between CAC and osteoporosis? Dr. Matt Budoff now speaking at #WCIRDC25
β™₯️‴️ CAC associated with‡️ bone denisity: osteoporosis =CV risk
β™₯️ Disease process:osteoclast πŸ†š osteoblasts
β™₯️ Osteopontin may promote atherosclerosis
β™₯️ therapies for osteoporosis need to be considered
#CardioSky

14.12.2024 20:57 β€” πŸ‘ 19    πŸ” 7    πŸ’¬ 1    πŸ“Œ 2
Post image

πŸŽ‰ The HEARTS Act has passed the Senate & heads to President Biden's desk! HRS, a proud Smart Heart Sports Coalition member, led a grassroots effort urging legislators to act. Soon, schools nationwide will have AEDs, CPR training, & emergency plansβ€”lifesaving tools for every kid ❀️smartheartsports.com

12.12.2024 14:12 β€” πŸ‘ 14    πŸ” 7    πŸ’¬ 1    πŸ“Œ 1
Preview
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches Erin Michos, MD examines unique HFpEF mechanisms for women and implications for sex-specific treatment.

Here at the #WCIRDC2024 conference where I presented in #HFpEF and sex specific considerations for women. I shared a summary of this with #HCPLive . #CardioSky #WomensHeartHealth

www.hcplive.com/view/erin-mi...

14.12.2024 00:43 β€” πŸ‘ 23    πŸ” 8    πŸ’¬ 0    πŸ“Œ 0

I have heard about Lp(a) being somewhat variable and that it may change during acute illness. I wonder if testing recommendations will change as more data is produced by these trials. Should individuals with borderline values have their Lp(a) rechecked in the future?

13.12.2024 20:24 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0